Excitotoxicity is a pathological process in which excessive or prolonged activation of glutamate receptors leads to neuronal death. It is a fundamental mechanism in acute brain injury (stroke, trauma) and chronic neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[1][2]. The term "excitotoxicity" was coined by John Olney in 1969, who observed that monosodium glutamate could cause brain lesions in mice[3]. This discovery laid the foundation for understanding how excessive glutamate signaling can be neurotoxic.
Excitotoxicity occurs when the balance between excitatory and inhibitory neurotransmission is disrupted, leading to excessive glutamate signaling. Under normal conditions, glutamate acts as the primary excitatory neurotransmitter in the central nervous system, but pathological elevations lead to neuronal damage through a cascade of intracellular events:
The ionotropic glutamate receptors are divided into three major families, each with distinct pharmacological and physiological properties:
| Receptor Type | Ion Channel | Permeability | Key Functions | Associated Diseases |
|---|---|---|---|---|
| NMDA | Ligand-gated, voltage-dependent | Ca2+, Na+, K+ | Learning, memory, synaptic plasticity | AD, PD, ALS, HD |
| AMPA | Ligand-gated | Na+, K+ (some Ca2+) | Fast excitatory transmission | ALS, PD |
| Kainate | Ligand-gated | Na+, K+ | Modulation of synaptic transmission | ALS, epilepsy |
| mGluR | G-protein coupled | Indirect | Regulation of neurotransmitter release | AD, PD |
NMDA Receptors are particularly important in excitotoxicity because of their high calcium permeability. They consist of NR1 subunits combined with NR2 (NR2A-NR2D) or NR3 subunits. The subunit composition determines the channel's properties and localization. NR2B-containing receptors are enriched in extrasynaptic locations and are preferentially implicated in excitotoxic signaling (Hardingham & Bading, 2003).
AMPA Receptors mediate fast excitatory neurotransmission. Most AMPA receptors are GluA1-4 subunits that form tetrameric channels. Some subunits (GluA2) are calcium-impermeable when edited, while others allow calcium influx. In neurodegenerative diseases, alterations in GluA2 editing and expression contribute to excitotoxic vulnerability (Van Den Bosch et al., 2002).
Astrocytes and neurons express excitatory amino acid transporters (EAATs) that regulate extracellular glutamate levels. These transporters are crucial for preventing toxic glutamate accumulation:
Loss or dysfunction of EAAT2 is a hallmark of ALS and contributes to excitotoxicity in multiple neurodegenerative diseases. Reduced GLT-1 expression has been documented in AD, PD, and ALS brains (Lin et al., 2012).
Excitotoxicity contributes to synaptic dysfunction and neuronal loss in Alzheimer's disease through multiple mechanisms. Aβ oligomers potentiate NMDA receptor-mediated calcium influx, leading to calpain activation and synaptic protein cleavage (Olivera et al., 2022). Additionally, Aβ disrupts glutamate transporter function on astrocytes, causing extracellular glutamate accumulation (Scimemi et al., 2014). Synaptic NMDA receptors, normally protective, become dysregulated in AD, leading to pathological calcium signaling.
The amyloid precursor protein (APP) and its proteolytic products directly influence glutamate receptor function. Aβ interacts with prion protein and cellular prion protein (PrP^C) to enhance NMDA receptor activity (Hyman et al., 1994). Furthermore, tau pathology exacerbates excitotoxic damage by impairing mitochondrial transport and function (Roe et al., 2024).
In Parkinson's disease, excitotoxicity interacts with dopaminergic neuron vulnerability. The substantia nigra pars compacta has inherently low calcium buffering capacity, making dopaminergic neurons particularly susceptible to calcium dysregulation (Surmeier et al., 2011). L-type calcium channels (Cav1.3) drive rhythmic pacemaking that elevates basal calcium levels, priming neurons for excitotoxic damage.
Mitochondrial dysfunction in PD (from PINK1, PARKIN, LRRK2 mutations) primes neurons for excitotoxic death through reduced ATP production and impaired calcium homeostasis (Exner et al., 2012). Alpha-synuclein aggregation further disrupts glutamate transport and enhances excitotoxic vulnerability (Martin et al., 2023).
ALS features prominent excitotoxicity with mutations in SOD1 causing glutamate transporter (EAAT2) downregulation (Lin et al., 2012). Over 90% of ALS cases show EAAT2 dysfunction, leading to elevated extracellular glutamate. TDP-43 pathology (in 95% of ALS cases) also contributes to excitotoxic mechanisms through RNA metabolism disruption (Barmada et al., 2014).
The C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS and frontotemporal dementia, leads to RNA toxicity and dipeptide repeat proteins that impair glutamate transport (Zhang et al., 2023).
Huntington's disease shows excitotoxic vulnerability through expanded polyglutamine repeats in the HTT gene. Mutant huntingtin disrupts mitochondrial function and increases NMDA receptor activity, leading to selective striatal neuron death (Fan et al., 2012). The striatum is particularly vulnerable due to its high density of NMDA receptors and GABAergic medium spiny neurons.
Transcriptional dysregulation in HD affects glutamate receptor subunit expression, with reduced NR2A/NR2B ratios contributing to enhanced excitotoxicity (Sonntag et al., 2018).
Excessive calcium influx activates calpains, calcium-dependent cysteine proteases that cleave numerous cellular substrates:
Calpain activation also leads to activation of downstream caspases, amplifying the cell death cascade (Vosler et al., 2009). The calpain-caspase cascade represents a final common pathway for excitotoxic neuronal death.
Mitochondria accumulate calcium during excitotoxic stress through the mitochondrial calcium uniporter (MCU). This leads to:
The mitochondrial permeability transition pore (mPTP) is a key mediator of excitotoxic neuronal death. Cyclophilin D (CyPD) is a critical regulator of mPTP opening, and genetic deletion of Ppif (CyPD) confers neuroprotection (Baines et al., 2005).
Choi DW. Excitotoxic cell death. 1992. ↩︎
Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. 2010. ↩︎
Olney JW. Brain lesions in mice treated with monosodium glutamate. 1969. ↩︎
Mehta A, Prabhakar M, Kumar P, et al. 'Excitotoxicity: cascade of events'. 2013. ↩︎
Bellinger ML, Bellinger C, Bellinger G. Calcium dysregulation in excitotoxicity. 2008. ↩︎
Vosler PS, Chen J. Calpain-mediated signaling in excitotoxicity. 2009. ↩︎
Bernardi P, Di Lisa F, Pozzan T. Mitochondrial permeability transition in neurodegeneration. 2022. ↩︎
Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegeneration. 1993. ↩︎